Correlation Between Molecular Partners and Eliem Therapeutics

Can any of the company-specific risk be diversified away by investing in both Molecular Partners and Eliem Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Molecular Partners and Eliem Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.

By analyzing existing cross correlation between Molecular Partners AG and Eliem Therapeutics, you can compare the effects of market volatilities on Molecular Partners and Eliem Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Molecular Partners with a short position of Eliem Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Molecular Partners and Eliem Therapeutics.

Diversification Opportunities for Molecular Partners and Eliem Therapeutics

-0.34

Correlation Coefficient

Molecular Partners  Eliem Therapeutics

Very good diversification

The 3 months correlation between Molecular and Eliem is -0.34. Overlapping area represents the amount of risk that can be diversified away by holding Molecular Partners AG and Eliem Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Eliem Therapeutics and Molecular Partners is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Molecular Partners AG are associated (or correlated) with Eliem Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Eliem Therapeutics has no effect on the direction of Molecular Partners i.e., Molecular Partners and Eliem Therapeutics go up and down completely randomly.

Pair Corralation between Molecular Partners and Eliem Therapeutics

Given the investment horizon of 90 days Molecular Partners AG is expected to generate 1.45 times more return on investment than Eliem Therapeutics. However, Molecular Partners is 1.45 times more volatile than Eliem Therapeutics. It trades about 0.04 of its potential returns per unit of risk. Eliem Therapeutics is currently generating about -0.24 per unit of risk. If you would invest  564.00  in Molecular Partners AG on September 2, 2024 and sell it today you would earn a total of  18.00  from holding Molecular Partners AG or generate 3.19% return on investment over 90 days.

Time Period	3 Months [change]
Direction	Moves Against
Strength	Insignificant
Accuracy	96.88%
Values	Daily Returns

Molecular Partners AG  vs.  Eliem Therapeutics

Molecular Partners

Risk-Adjusted Performance

3 of 100

Insignificant

Compared to the overall equity markets, risk-adjusted returns on investments in Molecular Partners AG are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. In spite of very weak essential indicators, Molecular Partners displayed solid returns over the last few months and may actually be approaching a breakup point.

Eliem Therapeutics

Risk-Adjusted Performance

0 of 100

Very Weak

Over the last 90 days Eliem Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of weak performance in the last few months, the Stock's basic indicators remain very healthy which may send shares a bit higher in January 2025. The recent disarray may also be a sign of long period up-swing for the firm investors.

Pair Trading with Molecular Partners and Eliem Therapeutics

The main advantage of trading using opposite Molecular Partners and Eliem Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Molecular Partners position performs unexpectedly, Eliem Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Eliem Therapeutics will offset losses from the drop in Eliem Therapeutics' long position.

The idea behind Molecular Partners AG and Eliem Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.

Check out your portfolio center.

Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sign In To Macroaxis module to sign in to explore Macroaxis' wealth optimization platform and fintech modules.